-

insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Leaders to Participate in Multiple Industry Forums Throughout Healthcare Week

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company update, including its AI-enabled discovery engine and therapeutic candidates advancing to the clinic, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, at 4:00 p.m. PT in San Francisco.

Additional insitro participation at healthcare week events:

  • Longwood Healthcare Leaders’ San Francisco CEO Conference
    Daphne Koller, Ph.D., will participate on the panel "Identifying Next-Generation Therapeutics" on Sunday, Jan. 11, at 1:30 p.m. PT
  • KPMG + Goodwin Symposium
    Mary Rozenman, Ph.D., CFO and CBO, will join the panel "Transaction to Transformation: Innovative End-to-End Strategies for Life Sciences Companies Amid Market Volatility" on Wednesday, Jan. 14, at 11:30 a.m. PT.

insitro's J.P. Morgan presentation will be made available on the insitro website following the event.

About insitro

insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro’s platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience. insitro is backed by world-class investors and has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships.

Contacts

Media contact
Eric McKeeby
eric@insitro.com

Industry:

insitro

Release Versions
English

Contacts

Media contact
Eric McKeeby
eric@insitro.com

More News From insitro

insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of Hideo Makimura as Chief Medical Officer, effective Sept. 14. Makimura will lead clinical development strategy and execution as insitro advances its AI-derived metabolic disease and neuroscience pipeline toward first-in-human trials — a key step in the company’s evolution toward clinical-stage development. Makimura joins as insitro transitions its initial...

insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions

NEW ORLEANS--(BUSINESS WIRE)--insitro, the physical AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) therapeutic development program during a podium presentation at the American Diabetes Association (ADA) 86th Scientific Sessions. The data demonstrate that liver-targeted silencing of IRS1 reduced fibrosis progression and injury-associated circulatory biomarkers in an industry-standard fibrogenic prec...

insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS. BMS has nominated two additional targets...
Back to Newsroom